Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells.
Mooney AH, Draper SL, Burn OK, Anderson RJ, Compton BJ, Tang C, Farrand KJ, Di Lucia P, Ravà M, Fumagalli V, Giustini L, Bono E, Godfrey DI, Heath WR, Yuan W, Chisari FV, Guidotti LG, Iannacone M, Sidney J, Sette A, Gulab SA, Painter GF, Hermans IF. Mooney AH, et al. Among authors: fumagalli v. JHEP Rep. 2024 Feb 12;6(5):101038. doi: 10.1016/j.jhepr.2024.101038. eCollection 2024 May. JHEP Rep. 2024. PMID: 38694959 Free PMC article.
Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination.
Fumagalli V, Ravà M, Marotta D, Di Lucia P, Bono EB, Giustini L, De Leo F, Casalgrandi M, Monteleone E, Mouro V, Malpighi C, Perucchini C, Grillo M, De Palma S, Donnici L, Marchese S, Conti M, Muramatsu H, Perlman S, Pardi N, Kuka M, De Francesco R, Bianchi ME, Guidotti LG, Iannacone M. Fumagalli V, et al. Nat Immunol. 2024 Apr;25(4):633-643. doi: 10.1038/s41590-024-01787-z. Epub 2024 Mar 14. Nat Immunol. 2024. PMID: 38486021 Free PMC article.
CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus.
Andreata F, Moynihan KD, Fumagalli V, Di Lucia P, Pappas DC, Kawashima K, Ni I, Bessette PH, Perucchini C, Bono E, Giustini L, Nguyen HC, Chin SM, Yeung YA, Gibbs CS, Djuretic I, Iannacone M. Andreata F, et al. Among authors: fumagalli v. Sci Transl Med. 2024 Jan 10;16(729):eadi1572. doi: 10.1126/scitranslmed.adi1572. Epub 2024 Jan 10. Sci Transl Med. 2024. PMID: 38198572
Inhibition of the lysine demethylase LSD1 modulates the balance between inflammatory and antiviral responses against coronaviruses.
Mazzarella L, Santoro F, Ravasio R, Fumagalli V, Massa PE, Rodighiero S, Gavilán E, Romanenghi M, Duso BA, Bonetti E, Manganaro L, Pallavi R, Trastulli D, Pallavicini I, Gentile C, Monzani S, Leonardi T, Pasqualato S, Buttinelli G, Di Martino A, Fedele G, Schiavoni I, Stefanelli P, Meroni G, de Francesco R, Steinkuhler C, Fossati G, Iannacone M, Minucci S, Pelicci PG. Mazzarella L, et al. Among authors: fumagalli v. Sci Signal. 2023 Dec 19;16(816):eade0326. doi: 10.1126/scisignal.ade0326. Epub 2023 Dec 19. Sci Signal. 2023. PMID: 38113337
Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine.
Grandi A, Tomasi M, Ullah I, Bertelli C, Vanzo T, Accordini S, Gagliardi A, Zanella I, Benedet M, Corbellari R, Di Lascio G, Tamburini S, Caproni E, Croia L, Ravà M, Fumagalli V, Di Lucia P, Marotta D, Sala E, Iannacone M, Kumar P, Mothes W, Uchil PD, Cherepanov P, Bolognesi M, Pizzato M, Grandi G. Grandi A, et al. Among authors: fumagalli v. Vaccines (Basel). 2023 Sep 29;11(10):1546. doi: 10.3390/vaccines11101546. Vaccines (Basel). 2023. PMID: 37896949 Free PMC article.
A fluorescent reporter model for the visualization and characterization of TDC.
Fiore A, Sala E, Laura C, Riba M, Nelli M, Fumagalli V, Oberrauch F, Mangione M, Cristofani C, Provero P, Iannacone M, Kuka M. Fiore A, et al. Among authors: fumagalli v. Eur J Immunol. 2023 Dec;53(12):e2350529. doi: 10.1002/eji.202350529. Epub 2023 Oct 2. Eur J Immunol. 2023. PMID: 37741290
Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine.
Grandi A, Tomasi M, Ullah I, Bertelli C, Vanzo T, Accordini S, Gagliardi A, Zanella I, Benedet M, Corbellari R, Lascio GD, Tamburini S, Caproni E, Croia L, Ravà M, Fumagalli V, Lucia PD, Marotta D, Sala E, Iannacone M, Kumar P, Mothes W, Uchil PD, Cherepanov P, Bolognesi M, Pizzato M, Grandi G. Grandi A, et al. Among authors: fumagalli v. Res Sq [Preprint]. 2023 May 25:rs.3.rs-2788726. doi: 10.21203/rs.3.rs-2788726/v1. Res Sq. 2023. PMID: 37292970 Free PMC article. Updated. Preprint.
Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses.
Fumagalli V, Di Lucia P, Ravà M, Marotta D, Bono E, Grassi S, Donnici L, Cannalire R, Stefanelli I, Ferraro A, Esposito F, Pariani E, Inverso D, Montesano C, Delbue S, Perlman S, Tramontano E, De Francesco R, Summa V, Guidotti LG, Iannacone M. Fumagalli V, et al. EMBO Mol Med. 2023 May 8;15(5):e17580. doi: 10.15252/emmm.202317580. Epub 2023 Mar 22. EMBO Mol Med. 2023. PMID: 36946379 Free PMC article.
SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence.
Gioia U, Tavella S, Martínez-Orellana P, Cicio G, Colliva A, Ceccon M, Cabrini M, Henriques AC, Fumagalli V, Paldino A, Presot E, Rajasekharan S, Iacomino N, Pisati F, Matti V, Sepe S, Conte MI, Barozzi S, Lavagnino Z, Carletti T, Volpe MC, Cavalcante P, Iannacone M, Rampazzo C, Bussani R, Tripodo C, Zacchigna S, Marcello A, d'Adda di Fagagna F. Gioia U, et al. Among authors: fumagalli v. Nat Cell Biol. 2023 Apr;25(4):550-564. doi: 10.1038/s41556-023-01096-x. Epub 2023 Mar 9. Nat Cell Biol. 2023. PMID: 36894671 Free PMC article.
24 results